February 29-March 2

Americas Committee for Treatment and Research in Multiple Sclerosis Forum Presentations

February 23-25

Americas Committee for Treatment and Research in Multiple Sclerosis Forum Presentations

February 24-26

Americas Committee for Treatment and Research in Multiple Sclerosis Forum Presentations

Ofatumumab – B Cell Therapy

Cumulative Pregnancy Outcomes in Patients With Multiple Sclerosis Following Maternal Exposure to Ofatumumab: Results From the Novartis Safety Database

Bove R. et al
Poster: P510
Abstract

B-Cell Depletion and Efficacy Outcomes of Ofatumumab Are Consistent Across Different Body Mass Index Categories: Insights From ASCLEPIOS I and II Trials

Cross AH. et al
Poster: P098
Abstract

Ofatumumab Reduces Clinical and Radiological Activity in People with Recently Diagnosed Treatment-Naive Relapsing Multiple Sclerosis Irrespective of Baseline Serum Neurofilament Light Chain Levels

Pardo G. et al
Poster: P031
Abstract

Prognostic Value of Serum Neurofilament Light Chain for Disease Activity in Patients With Relapsing Multiple Sclerosis: Results From Subgroup Analysis Based on Body Mass Index and Age from the Phase 3 ASCLEPIOS I/II Trials

Cross AH. et al
Poster: P037
Abstract

Baseline Serum Neurofilament Light Chain Levels Predict Future Disease Activity Irrespective of Race/Ethnicity: Results From the Phase 3 ASCLEPIOS I/II Trials

Delgado S. et al
Poster: P036
Abstract

Prognostic Value of On-Treatment Serum Neurofilament Light Chain for New or Enlarging T2 Lesions in People With Relapsing Multiple Sclerosis: Pooled Analysis of the ASCLEPIOS I/II Trials

Leist T. et al
Poster: P032
Abstract

Ofatumumab Attenuates Cortical Microglial Activity in Patients With Relapsing Forms of Multiple Sclerosis Following B-cell depletion: Results From a 9-month Study

Singhal T. et al
Poster: P222
Abstract

Patient and Physician Perspectives on the Wearing-Off Effect in Multiple Sclerosis: Results from Structured Interviews

Alvarez E. et al
Poster: P437
Abstract

Ofatumumab in Different RMS Patient Populations in Everyday Clinical Practice in Germany

Nelles G. et al
Poster: P467
Abstract

An Expert Delphi Panel to Understand Potential Ofatumumab Injection-Related Reactions Among Patients with Relapsing Forms of Multiple Sclerosis

Saidha S. et al
Poster: P157
Abstract

Immune Response to Influenza Vaccine in Patients With Relapsing Multiple Sclerosis Treated With Ofatumumab: Results From an Open-Label, Multicenter, Phase 4 Study

Subei A. et al
Poster: P272
Abstract

Real-world Change in Annualized Relapse Rate Following Initiation of Ofatumumab in Patients with Multiple Sclerosis

Tai MH. et al
Poster: P489
Abstract

KAIROS: Ofatumumab in Patients With Relapsing Remitting Multiple Sclerosis who Previously Received Another Disease-modifying Therapy

Bischof F. et al
Poster: P486
Abstract
Siponimod

Longitudinal Observation of SPMS Patients Treated with Siponimod in
Germany – Three Years Interims Data from Real World Study AMASIA

Hoffmann O. et al
Poster: P376
Abstract
MS portfolio

A Prospective Data Collection to Evaluate Utility and Added Value of Serum NfL in Multiple Sclerosis - First Interim Insights from NeofiLos

Ziemssen T. et al
Poster: P033
Abstract

NeofiLos – Rationale, Design, Patient Characteristics (First Interim Data)

Ziemssen T. et al
Poster: P034
Abstract

Eye Movement Biomarkers for Classification of Multiple Sclerosis Progression vs Non-Progression in a Cohort of Multiple Sclerosis Patients

Giacomini PS. et al
Poster: P043
Abstract

MLR ID: 416384

A Network Meta-Analysis of Randomized Controlled Trials to Evaluate the Comparative Efficacy of Disease-Modifying Therapies for Patients with Relapsing Multiple Sclerosis

E-poster: P047
Abstract

Findings From OLIKOS: Baseline Immunoglobulin and B-Cell Concentrations in Patients Who Switch From Ocrelizumab to Ofatumumab

E-poster: P077
Abstract

Quality of Life and Treatment Satisfaction with Ofatumumab and Other DMTs in MS

E-poster: P457
Abstract

Interim Results of an Open Label Study to Assess Humoral Immune Response to COVID 19 mRNA Vaccine in Participants with Relapsing Multiple Sclerosis Treated with Ofatumumab

E-poster: P101
Abstract

Safety and Tolerability of Conversion to Siponimod in Patients with Advancing Relapsing Multiple Sclerosis: A Subgroup Analysis by Race and Ethnicity of EXCHANGE Interim Data

E-poster: P109
Abstract

Evaluating Humoral Immune Response to mRNA COVID 19 Vaccines in Siponimod treated Patients with Advancing Forms of Relapsing Multiple Sclerosis: A COVID 19 Vaccine Sub study of Phase 3b EXCHANGE Trial

E-poster: P133
Abstract

Longitudinal Analysis of Adaptive Immunity Following Additional SARS-CoV-2 Vaccination in MS Patients on Anti-CD20 Therapies and Sphingosine-1-phosphate Receptor Modulators

E-poster: P141
Abstract
Cookie Settings